石藥集團(01093.HK):布洛芬片通過一致性評價
格隆匯12月11日丨石藥集團(01093.HK)宣佈,公司附屬公司石藥集團歐意藥業有限公司開發的"布洛芬片(0.1g)"已獲中國國家藥品監督管理局批准通過仿製藥質量和療效一致性評價。
布洛芬片為解熱鎮痛類非處方藥品,用於緩解輕至中度疼痛如頭痛、關節痛、偏頭痛、牙痛、肌肉痛、神經痛、痛經,也用於普通感冒或流行性感冒引起的發熱。
布洛芬片為集團非處方藥品的重點產品之一,是國內首家通過一致性評價的同類產品。通過一致性評價,表明該產品質量和療效與原研藥品一致,為患者提供優質優價的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.